Axovant: Slumps on delay in study of gene therapy for Parkinson's

Sio Gene Therapies

30/10/2020 11:55

** Drug developer  AXGT.O  among the biggest percentage
losers across indexes premarket at $2.39, down 34.5%
    ** Co says it expects delay in enrolment of patients in a
planned clinical study of its experimental gene therapy for
Parkinson's disease called AXO-Lenti-PD, due to delays in the
manufacturing process at partner Oxford Biomedica  urn:newsml:reuters.com:*:nGNX5MP4Wl
    ** Manufacturing of several batches is now underway and
planned at Oxford Biomedica with a goal of generating material
for use in future clinical trials as soon as possible, AXGT says
    ** AXGT expects to provide an update on program timelines in
the first quarter of 2021
    ** Up to Thursday's close, AXGT down ~29% YTD

 (Reporting by Manojna Maddipatla in Bengaluru)
 ((manojna.kalyani@thomsonreuters.com; within the U.S. +1 646
223 8780, outside the U.S. +91  80 6749 1692))